Breakthrough in Long COVID: An investigator-initiated trial (IIT) with Hyundai Bioscience's Xafty by UCSD
SAN DIEGO, Sept. 17, 2024 /PRNewswire/ -- Hyundai Bioscience USA announced that it has signed an MOU with theUniversity of California San Diego (UCSD) to conduct an investigator-initiated trial to evaluate the efficacy of Xafty®, a niclosamide-based antiviral developed by its Korean headquarters,...
Hyundai Bioscience announces XAFTY®, a groundbreaking broad-spectrum antiviral capable of treating COVID-19, mpox, and dengue
* Hyundai Bioscience presents development updates of its broad-spectrum antiviral at the "Disease Prevention and Control Summit 2024" held in Philadelphia, USA. SEOUL, South Korea, Sept. 11, 2024 /PRNewswire/ -- Dr. Heung-Jeong Woo, a vice president of Hyundai Bioscience shared insights on the...
Hyundai Bioscience to conduct phase 3 clinical trial for high-risk group of COVID-19 patients with the goal of emergency use authorization
* "Xafty® can be the only oral COVID-19 treatment that can be prescribed to high-risk group patients who cannot take Paxlovid®" * "While maintaining the current process for emergency use authorization for mild-to-moderate COVID-19 patients, Hyundai Bioscience will expedite Phase 3 clinical tr...
ADM Korea Announces Niclosamide-based Metabolic Anticancer Drug's First Clinical Trial Target as 'Prostate Cancer Patients Resistant to Hormone Therapy'
* IND for clinical study for combination therapy with hormone therapy in prostate cancer patients to be submitted in August, 2024. * Niclosamide-based metabolic anticancer drug aims to block signaling pathways that allow cancer cells to evade anticancer effects, potentially solving the issue ...
Hyundai Bioscience succeeds in developing 'Multi-treatment for mosquito-borne viral infections' including Dengue Fever
* Developed a 'Niclosamide-based multi-treatment drug' that can simultaneously treat mosquito-borne viral infections such as four serotypes of dengue virus, Zika, Chikungunya, and Yellow Fever. * Accelerating preparations for dengue fever basket clinical trial scheduled to be conducted inBraz...
Hyundai Bioscience's antiviral for Dengue Fever to enter clinical trials in Brazil
* "Aiming to offer a Dengue antiviral treatment course in $100 price range" * Hyundai Bioscience decides to conduct dengue clinical trials in Brazil, which has the largest number of Dengue patients and offers a fast-track approval SEOUL, South Korea, April 25, 2024 /PRNewswire/ -- Hyundai Biosc...
Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer
* The only solution for intractable cancer caused by mutations in the p53 gene * Planning clinical trials targeting cancer patients with no available treatment due to p53 gene mutations SEOUL, South Korea, April 25, 2024 /PRNewswire/ -- Hyundai Bioscience announced onApril 25th that its clinica...
Hyundai Bioscience announces its successful result from a preclinical study of a Niclosamide-based oral anticancer drug to treat triple-negative breast cancer
* Clinical trials of Niclosamide-based oral metabolic anticancer drug to commence for patients with difficult-to-treat cancers such as triple-negative breast cancer and pancreatic cancer * Niclosamide-based oral anticancer drug project to be carried out by the new subsidiary of Hyundai Biosci...
Global clinical development on Dengue antiviral candidate will start, Hyundai Bioscience strives to win emergency use authorization
SEOUL, South Korea, April 19, 2024 /PRNewswire/ -- South Korea's biotechnology
company Hyundai Bioscience (CEO Oh Sang-gi,www.hyundaibioscience.com
Global clinical development on Dengue antiviral candidate will start, Hyundai Bioscience strives to win emergency use authorization
SEOUL, South Korea, April 18, 2024 /PRNewswire/ -- South Korea's biotechnology
company Hyundai Bioscience (CEO Oh Sang-gi,www.hyundaibioscience.com
The 'Penicillin' of Antivirals, Xafty by Hyundai Bioscience, Opened a New Era of Treating Respiratory Viral Infections with Single Drug
- Professor Heungjeong Woo of Hallym University College of Medicine, announced the result of Xafty's clinical study at Emerging Science Session of the American Society for Microbiology (ASM) Microbe 2023 - Dr. Jo White evaluated Xafty's clinical results as "The birth of Penicillin of Antivirals"...
Chemotherapy may be completed within 8 days with two doses of Polytaxel, an innovative anticancer drug from South Korea's biotech firm
* Polytaxel, a novel pain-free anticancer drug, may not require break periods * A new standard of care, more convenient than docetaxel, is suggested * Hyundai Bioscience to enter clinical trial on pancreatic cancer in Australia * Patient-centered chemotherapy to enable outpatients to live nor...
A novel universal antiviral drug introduced in Korea
- Hyundai Bioscience launches CP-COV03 Phase 2 clinical trials - "To be an innovative medicine like penicillin that led to victory in the bacterial war" - Significant changes to the 'vaccine-dependent' virus response system SEOUL, South Korea, May 12, 2022 /PRNewswire/ -- The birth of a universa...
CP-COV03, a niclosamide-based oral antiviral drug, under study as possible cure for COVID-19 variants
SUMMARY CP-COV03, a niclosamide-based oral antiviral drug, to cure COVID-19 variants CP-COV03 is a broad-spectrum antiviral drug candidate, developed by Hyundai Bioscience to treat COVID-19. Its active pharmaceutical ingredient is niclosamide, an anthelmintic drug, and is expected to work on var...
A 'Game Changer' COVID-19 drug from Korea was introduced in a world class academic journal
SEOUL South Korea, May 23, 2021 /PRNewswire/ -- Hyundai Bioscience (KOSDAQ 048410) announced on the 24th that CNPharm, its major shareholding bio tech company, published an article containing the research results of CP-COV03, a Niclosamide-based oral treatment for COVID-19 based on its proprietar...
An oral antiviral drug from Korea may be a problem solver for COVID-19
SEOUL, South Korea, May 13, 2021 /PRNewswire/ -- Hyundai Bioscience (KOSDAQ 048410) announced that Dr.Jin-Ho Choi, a Chief Scientist of its major shareholding bio tech company CNPharm and Chair Professor at Dankook University, presented the study titled 'COVID-19 Game Changer Drug – a novel orga...
CNPharm has succeeded in maintaining IC100 for 24 hours with one injection
- Trail-blazing diversification of the repurposing of Niclosamide - Full-scale clinical preparation of injections for severely ill patients SEOUL, South Korea, April 19, 2021 /PRNewswire/ -- Hyundai Bioscience (Symbol 048410), a KOSDAQ listed company, announced on the 19th that its major sharehol...
Hyundai Bioscience leads in the repurposing of Niclosamide
SEOUL, South Korea, April 8, 2021 /PRNewswire/ -- A research paper by a South Korean bio tech company that demonstrated the drug repurposing of Niclosamide, an anthelmintic known to have excellent therapeutic efficacy against novel coronavirus infection (COVID-19), was published in the world-reno...
Hyundai Bioscience Develops Injection Drug for Potential Treatment of Severe Cases of COVID-19
SEOUL, South Korea, Dec. 22, 2020 /PRNewswire/ -- Hyundai Bioscience (KOSDAQ symbol: 048410) announced on the 23rd, December 2020, that CNPharm, its major shareholding bio tech company, has succeeded in developing 'Poly-COV01,' an injection drug for thepotential treatment of patients with severe ...
Hyundai Bioscience announced that its COVID-19 oral drug solved Niclosamide's inhibitory concentration problem
SEOUL, South Korea, Dec. 8, 2020 /PRNewswire/ -- Hyundai Bioscience (KOSDAQ symbol: 048410) released a report onDecember 8th that CP-COV03, its new COVID-19 oral drug candidate, successfully demonstrated a 100% inhibitory concentration level in the blood (IC100) for 12 hours against viral activit...
